【Lauoria Pharmaceuticals】Strengthening of Intellectual Property Rights through US Patent Grant for IRAK-M Protein Degradation Inducer | July 2026

Overview of Patent Grant

Lauoria Pharmaceuticals' consolidated subsidiary, FIMEKSU, has received a patent grant in the United States for an IRAK-M protein degradation inducer. This compound is involved in cancer immune suppression and is expected to activate immune responses. Through further research and development and expanding intellectual property, the company aims to enhance long-term corporate value. This patent grant follows previous grants in Japan and Europe, strengthening patent rights in key markets. The impact on the consolidated performance in 2026 is minimal, but this represents an important intellectual property for future commercialization.

Future Outlook and Corporate Activities

FIMEKSU continues to advance drug discovery research utilizing RaPPIDSTM technology, progressing pipeline research and development, and commercialization efforts. The US patent grant enhances intellectual property rights for compounds including FIM-001, supporting long-term business expansion and partnership development. The company will continue to pursue domestic and international patent examinations, leveraging its drug discovery platform to accelerate new drug development.